Celldex Therapeutics (Celldex Therapeutics) Days Sales Outstanding

: 31.81 (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

Celldex Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $1.44 Mil. Celldex Therapeutics's Revenue for the three months ended in Dec. 2023 was $4.13 Mil. Hence, Celldex Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 31.81.

The historical rank and industry rank for Celldex Therapeutics's Days Sales Outstanding or its related term are showing as below:

CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.19 Med: 71.68 Max: 213.35
Current: 49.41

During the past 13 years, Celldex Therapeutics's highest Days Sales Outstanding was 213.35. The lowest was 40.19. And the median was 71.68.

CLDX's Days Sales Outstanding is ranked better than
69.71% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs CLDX: 49.41

Celldex Therapeutics's Days Sales Outstanding increased from Dec. 2022 (15.16) to Dec. 2023 (31.81).

Celldex Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Celldex Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

213.35

69.30

77.46

40.19

78.88

Celldex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															15.16	78.37	243.79	11.13	31.81

Competitive Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Days Sales Outstanding falls into.

Celldex Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Celldex Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.347	+	2.628)	/	2 )	/	6.883	*	365
=	1.4875					/	6.883	*	365
=	78.88

Celldex Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.252	+	2.628)	/	2 )	/	4.131	*	365 / 4
=	1.44					/	4.131	*	365 / 4
=	31.81

Celldex Therapeutics (NAS:CLDX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Celldex Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (Celldex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

TCE2:Germany

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Executives

Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler	officer: Sen. VP & Ch Scientific Off.	30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh	officer: SVP of Corp. Affairs & Admin.	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young	officer: SVP, Chief Medical Officer	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci	director, officer: President and CEO	66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright	officer: Sr. VP & CCO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin	officer: SVP and CFO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi	officer: SVP of of Regulatory Affairs	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley	officer: SVP, Chief Product Dev Officer	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez	officer: SVP & General Counsel	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114